Press Release | June 17, 2025
Skyhawk Therapeutics Announces First Patient Dosed in Phase 2/3 FALCON-HD Trial of SKY-0515 for Huntington’s Disease
Read More
Press Release | May 28, 2025
Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
Read More
Press Release | May 27, 2025
GlycoEra AG Raises $130 Million to Advance Novel Pipeline of Extracellular Protein Degraders for the Treatment of Autoimmune Diseases
Read More
Press Release | May 22, 2025
ImCheck Reports High Remission Rates in AML Patients with ICT01 Combination Therapy at ASCO 2025
Read More
